



December 19, 2005

Can-Fite's Share will be included in the Tel-Tech share index of the Tel-Aviv Stock Exchange

The Tel-Aviv Stock Exchange (TASE) announced on December 18 that Can-Fite's shares will be included in the Tel-Tech index as of January 1, 2006.

The Tel-Tech index is a weighted index, based on the companies market capitalizations, composed of shares of technology based companies from the field of electronics, computers and life sciences as well as from shares of venture funds and investment companies, whose main income or value is derived from these fields and which are traded on the TASE.

Prof. Pnina Fishman, Can-fite's CEO, stated "the inclusion of Can-fite to this prestigious index is an acknowledgment in the value of the company and its importance, provides support to the biotechnology industry and will increase the transparency to Can-fite on one hand and the interest of financial institutions in the company on the other hand."

About Can-Fite

Can-Fite BioPharma Ltd. is a public company, traded on the Tel-Aviv Stock Exchange that is headquartered in Petach-Tikva, Israel. The company, which began its operations at the end of 2000 was founded based on the work by Professor Pnina Fishman, formerly a Tumor Immunologist in the Rabin Medical Center and currently the company's CEO, together with Dr Ilan Cohn, Patent Attorney and Senior Partner at Reinhold Cohn and Partners, a leading Israeli Patent Attorney firm. The Company has research laboratories and offices in Israel. The Company's lead drug, CF101, for the treatment of rheumatoid arthritis is currently in Phase II clinical trials and to date went through clinical trials in the USA, UK and Israel.

About CF101

CF101 is a small molecule, which is administered to patients orally. This drug, which is developed for the treatment of rheumatoid arthritis, was tested to date in clinical trials in the USA, UK and Israel. The drug is active against a wide variety of autoimmune and cancer diseases and has a preferential safety profile. The drug's main advantage is in its ability to specifically attack pathological cells without affecting healthy ones. In addition, the fact that the drug is administered orally in the form of a capsule creates a huge advantage vs. current treatments which are administered by IV infusion or injection, at much higher costs. The annual potential market for the treatment of rheumatoid arthritis is currently about US\$ 5 billion and is expected to rise at an annual rate of about 20%.

More information can be found at www.canfite.com